Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

References

• SwindellsSDiRienzoAGWilkinTRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionJAMA2006296780681416905786
   PubMed Web of Science ®Google Scholar
• MartínezEArnaizJAPodzamczerDThree-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patientsAIDS200721336736917255745
   PubMed Web of Science ®Google Scholar
• DejesusEYoungBMorales-RamirezJOSimplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patientsJ Acquir Immune Defic Syndr200951216317419357529
   PubMed Web of Science ®Google Scholar
• MartinABlochMAminJSimplification of antiretroviral therapy with tenofoviremtricitabine or abacavir lamivudine: a randomized, 96-week trialClin Infect Dis2009491591160119842973
   PubMed Web of Science ®Google Scholar
• WohlDABhattiLSmallCBSimplification to abacavir/lamivudine+atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non inferiority trialPLoS One20149e9618724825167
   PubMed Web of Science ®Google Scholar
• Di GiambenedettoSFabbianiMColafigliMA Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)J Antimicrob Chemother20136861364137223372058
   PubMed Web of Science ®Google Scholar
• BurgosJCrespoMFalcóVSimplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patientsJ Antimicrob Chemother201267102479248622729925
   PubMed Web of Science ®Google Scholar
• HIV/AIDS Italian Expert PanelLinee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-112172015 Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2442_allegato.pdfAccessed November 4, 2016
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services Last updated January 28, 2016; last reviewed January 28, 2016. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdfAccessed November 4, 2016
   Google Scholar
• ChurchillDWatersLAhmedNBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 Available from: http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdfAccessed November 4, 2016
   Google Scholar
• The Medicines Utilisation Monitoring CentreNational Report on Medicines use in Italy. Year 2015RomeItalian Medicines Agency2016 Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2015__AIFA.pdf
   Google Scholar
• CossariniFSalpietroSGalliLMonotherapy with atazanavir as a simplification strategy: results from an observational studyJ Acquir Immune Defic Syndr2012603e101e10322728751
   PubMed Web of Science ®Google Scholar
• PulidoFArribasJRDelgadoRLopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS2008222F1F9
   PubMed Web of Science ®Google Scholar
• ArribasJRClumeckNNelsonMThe MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load, 50 HIV-1 RNA copies/mL at baselineHIV Med201213739840522413874
   PubMed Web of Science ®Google Scholar
• ValantinMALambert-NiclotSFlandrePLong-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyJ Antimicrob Chemother201267369169522160145
   PubMed Web of Science ®Google Scholar
• BiermanWFvan AgtmaelMANijhuisMHIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS200923327929119114854
   PubMed Web of Science ®Google Scholar
• AngelettiCPezzottiPAntinoriAAntiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment startHIV Med201415316517424495188
   PubMed Web of Science ®Google Scholar
• RestelliUAndreoniMAntinoriABudget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceClinicoecon Outcomes Res2014640941425285019
   PubMedGoogle Scholar
• HillAHillTJoseSPozniakAPredicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018J Int AIDS Soc2014174 Suppl 31949725394006
   PubMed Web of Science ®Google Scholar
• Di GiambenedettoSFabbianiMQuiros RoldanETreatment simplification to atazanavir/ritonavir plus lamivudine versus maintenance of atazanavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in virologically-suppressed HIV-1-infected patients: 48-weeks results from a randomized trial (ATLAS-M)J Antimicrob ChemotherIn press2017
   Google Scholar
• SullivanSDMauskopfJAAugustovskiFBudget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue Health201417151424438712
   PubMed Web of Science ®Google Scholar
• IstitutoSuperioredi SanitàCentroOperativoAIDSAggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2012. [Characteristics of persons with HIV and AIDS in Italy – 31 December 2012]Not Ist Super Sanità20132678 Italian
   Google Scholar
• RestelliUScolariFBonfantiPNew highly active antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy)BMC Infect Dis20151532326259842
   PubMed Web of Science ®Google Scholar
• LlibreJMCardonaGSantosJRAntiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in SpainClinicoecon Outcomes Res2013521522123723714
   PubMedGoogle Scholar
• GazzardBMoecklinghoffCHillANew strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United KingdomClinicoecon Outcomes Res2012419320022888265
   PubMedGoogle Scholar